1. Cell Cycle/DNA Damage
  2. PPAR

Wy-14643 (Synonyms: Pirinixic acid)

Cat. No.: HY-16995 Purity: 99.69%
Handling Instructions

Wy-14643 is a potent agonist of PPARα, with EC50s of 0.63 μM, 32 μM for murine PPARα and PPARγ, and 5.0 μM, 60 μM, 35 μM for human PPARα, PPARγ and PPARδ, respectively.

For research use only. We do not sell to patients.

Wy-14643 Chemical Structure

Wy-14643 Chemical Structure

CAS No. : 50892-23-4

Size Price Stock Quantity
Free Sample (0.5-1 mg)   Apply now  
10 mM * 1 mL in DMSO USD 66 In-stock
Stock in Sweden
Estimated Time of Arrival: December 31
10 mg USD 60 In-stock
Stock in Sweden
Estimated Time of Arrival: December 31
50 mg USD 84 In-stock
Stock in Sweden
Estimated Time of Arrival: December 31
100 mg USD 120 In-stock
Stock in Sweden
Estimated Time of Arrival: December 31
250 mg USD 264 In-stock
Stock in Sweden
Estimated Time of Arrival: December 31
500 mg   Get quote  
1 g   Get quote  

* Please select Quantity before adding items.

View All PPAR Isoform Specific Products:

  • Biological Activity

  • Protocol

  • Technical Information

  • Purity & Documentation

  • References

Description

Wy-14643 is a potent agonist of PPARα, with EC50s of 0.63 μM, 32 μM for murine PPARα and PPARγ, and 5.0 μM, 60 μM, 35 μM for human PPARα, PPARγ and PPARδ, respectively.

IC50 & Target[1]

PPARα

0.63 μM (EC50)

PPARγ

32 μM (EC50)

In Vitro

Wy-14643 is an agonist of PPARα, with EC50s of 0.63 μM, 32 μM for murine PPARα and PPARγ, and 5.0 μM, 60 μM, 35 μM for human PPARα, PPARγ and PPARδ, respectively[1]. Wy-14643 (0, 10, 100 μM) enhances protein expression of PPAR-α in synovial fibroblasts. Wy-14643 (0, 10, 100 μM) shows inhibitroy effects on NO and PGE2 production in LPS-stimulated synovial fibroblasts. Wy-14643 also effectively downregulates expression of inflammatory mediators such as VCAM-1, ICAM-1, ET-1, and TF in synovial fibroblasts, blocks LPS-induced NF-kB activation, IkB phosphorylation, and NF-kB nuclear translocation in synovial fibroblasts, but Wy-14643 shows no effects in PPAR-α silenced cells[2].

In Vivo

Wy-14643 (10 mg/kg, i.v.) decreases hepatic injury and lipid peroxidation (MDA) levels in obese rats. Wy-14643 also causes increased SIRT1 activity in Sham and ischemia-reperfusion (IR) group, but shows no effects on SIRT3 protein expression. Wy-14643 enhances NAD+, and ATP levels, and prevents endoplasmic reticulum stress (ERS) in rats[3].

References
Preparing Stock Solutions
Concentration Volume Mass 1 mg 5 mg 10 mg
1 mM 3.0883 mL 15.4416 mL 30.8833 mL
5 mM 0.6177 mL 3.0883 mL 6.1767 mL
10 mM 0.3088 mL 1.5442 mL 3.0883 mL
Please refer to the solubility information to select the appropriate solvent.
Kinase Assay
[3]

Protein extracts are obtained using a mild lysis buffer (50 mM Tris-HCl pH 8, 125 mM NaCl, 1 mM DTT, 5 mM MgCl2, 1 mM EDTA, 10% glycerol, and 0.1% NP40). SIRT1 activity is measured using a deacetylase fluorometric assay kit. A total of 25 μL of assay buffer containing the same quantity of protein extracts (10 μg/μL) is added to all wells, and the fluorescence intensity is monitored every 2 min for 1 h using the fluorescence plate reader, applying an excitation wavelength of 355 nm and an emission wavelength of 460 nm. The results are expressed as the rate of reaction for the first 30 min, when there is a linear correlation between the fluorescence and this period of time[3]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Assay
[2]

Synovial fibroblasts are treated with LPS (100 μg/mL) in the presence or absence of Wy-14643. PPAR-α siRNA-transfected cells are also treated with LPS (100 μg/mL) together with Wy-14643. After stimulation, the production of NO is determined using Griess reagents. Briefly, 300 μL of supernatant is mixed with 100 μL of Griess reagent and 2.6 mL of deionized water. The mixture is incubated for 30 min at room temperature, and the absorbance at 548 nm is measured. The concentrations of NO in the supernatants are calculated from a standard curve[2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration
[2]

Synovial fibroblasts are treated with LPS (100 μg/mL) in the presence or absence of Wy-14643. PPAR-α siRNA-transfected cells are also treated with LPS (100 μg/mL) together with Wy-[2]Synovial fibroblasts are treated with LPS (100 μg/mL) in the presence or absence of Wy-14643. PPAR-α siRNA-transfected cells are also treated with LPS (100 μg/mL) together with Wy-14643. After stimulation, the production of NO is determined using Griess reagents. Briefly, 300 μL of supernatant is mixed with 100 μL of Griess reagent and 2.6 mL of deionized water. The mixture is incubated for 30 min at room temperature, and the absorbance at 548 nm is measured. The concentrations of NO in the supernatants are calculated from a standard curve[2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

References
Molecular Weight

323.8

Formula

C₁₄H₁₄ClN₃O₂S

CAS No.

50892-23-4

SMILES

O=C(O)CSC1=NC(NC2=CC=CC(C)=C2C)=CC(Cl)=N1

Storage
Powder -20°C 3 years
  4°C 2 years
In solvent -80°C 6 months
  -20°C 1 month
Shipping

Room temperature in continental US; may vary elsewhere

Solvent & Solubility

DMSO: 15 mg/mL

* "<1 mg/mL" means slightly soluble or insoluble. "≥" means soluble, but saturation unknown.

Purity: 99.69%

Inquiry Online

Your information is safe with us. * Required Fields.

Product name

 

Salutation

Applicant name *

 

Email address *

Phone number *

 

Organization name *

Country or Region *

 

Requested quantity *

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Wy-14643
Cat. No.:
HY-16995
Quantity: